Best for weight loss
The best GLP‑1 medications for weight loss in 2026
Reducing body weight in adults with BMI ≥ 27 with comorbidities or BMI ≥ 30.
Find the right weight loss treatment in 30 seconds
Quick decision tree — answer 2–4 questions, get a personalized recommendation. No email required.
Does your insurance cover weight-loss medication?
Most relevant drugs
Top-scored options for weight loss
Each score is our overall rating from the clinical rubric (effectiveness, safety, evidence, value). The left rule is color-keyed to the molecule.
8.9
/ 10
Form Health
Brand-name GLP-1 (Wegovy, Zepbound, etc.)
Read the full review →
8.8
/ 10
Zepbound
Tirzepatide
Read the full review →
8.7
/ 10
Mounjaro
Tirzepatide
Read the full review →
8.7
/ 10
Wegovy
Semaglutide
Read the full review →
Molecule key: Semaglutide Tirzepatide Oral Other GLP-1
Full ranking
Every GLP-1 we rank for weight loss
- Top pick1
Obesity-medicine telehealth that takes insurance
- Insurance-accepting (rare for GLP-1 telehealth)
- Board-certified obesity medicine physicians
- Brand-name only — no compounding gamble
FDA-approvedBrand-nameOnce-weekly injectionInsurance eligibleSee review8.9/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there. - 2Runner-upEditor's Choice
FDA-approved tirzepatide for weight loss
- Highest reported weight loss of any approved GLP-1 (avg ~21% in SURMOUNT-1)
- Dual GIP + GLP-1 mechanism
- FDA-approved for OSA + obesity (2024)
FDA-approvedBrand-nameOnce-weekly injectionDual GIP / GLP-1Insurance eligible8.8/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there.See reviewTrue cost · maint.$549/mo · 10mg+$150 - 3Also great
Tirzepatide for type 2 diabetes
- Significant A1C reduction
- Substantial weight loss as side benefit
Off-label useOnce-weekly injectionDual GIP / GLP-1Insurance eligible8.7/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there.See reviewTrue cost · maint.$549/mo · 7.5mg+$150 - 4Best for editor's choice#1· Editor's ChoiceEditor's ChoiceBest for CV Risk
FDA-approved semaglutide for chronic weight management
- Average 15% weight loss in clinical trials (STEP 1)
- FDA-approved with extensive safety record
- Weekly dosing
FDA-approvedBrand-nameOnce-weekly injectionGLP-1 receptor agonistInsurance eligibleMost transparent pricing8.7/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there.See reviewTrue cost · maint.$499/mo · 2.4mg - 5Editor's Choice
Eli Lilly oral GLP-1 pill for weight loss (Apr 2026 launch)
- Highest efficacy oral GLP-1 — approaches injection tirzepatide levels
- More flexible dosing (no strict empty-stomach window)
- Same dual GIP/GLP-1 mechanism as Zepbound
FDA-approvedBrand-nameDaily oral tabletInsurance eligibleSee review8.6/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there. - 6
Year-long metabolic reset with GLP-1
- 1-on-1 coaching included
- Behavior change framework
FDA-approvedBrand-nameOnce-weekly injectionSee review8.5/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there. - 7
Semaglutide approved for type 2 diabetes
- Strong A1C reduction in T2D
- Often covered by insurance for diabetes indication
Off-label useOnce-weekly injectionGLP-1 receptor agonistInsurance eligible8.5/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there.See reviewTrue cost · maint.$499/mo · 1mg
Quick comparison
Verified Jul 17, 2026| # | Product | Active ingredient | Starting price | True cost · maint. | FDA status | Score | |
|---|---|---|---|---|---|---|---|
| 1 | Form Health | Brand-name GLP-1 (Wegovy, Zepbound, etc.) | Best ·$99/mo | approved | Top ·8.9 | View → | |
| 2 | Zepbound | Tirzepatide | $1349/mo | $549/mo · 10mg+$150 | approved | 8.8 | View → |
| 3 | Mounjaro | Tirzepatide | $1349/mo | $549/mo · 7.5mg+$150 | off-label | 8.7 | View → |
| 4 | Wegovy Most transparent pricing | Semaglutide | $1349/mo | $499/mo · 2.4mg | approved | 8.7 | View → |
| 5 | Foundayo (orforglipron) | Orforglipron (oral small-molecule GLP-1) | $1349/mo | approved | 8.6 | View → | |
| 6 | Calibrate | Brand-name GLP-1 | $1990/mo | approved | 8.5 | View → | |
| 7 | Ozempic | Semaglutide | $997/mo | $499/mo · 1mg | off-label | 8.5 | View → |
| 8 | Sequence by WeightWatchers | Brand-name GLP-1 | Best ·$99/mo | approved | 8.4 | View → | |
| 9 | Wegovy Pill (oral semaglutide 25mg) | Semaglutide (oral, 25mg) | $1349/mo | approved | 8.3 | View → | |
| 10 | Ro Body | Semaglutide / Tirzepatide (brand or compounded) | $135/mo | approved | 8.2 | View → | |
| 11 | Noom Med | Brand-name GLP-1 | $149/mo | approved | 8.1 | View → | |
| 12 | Hims & Hers Weight Loss Best value | Compounded Semaglutide | $199/mo | Best ·$249/mo · 1.0mg+$50 | compounded | 7.7 | View → |
| 13 | PlushCare Weight Loss | Brand-name GLP-1 | Best ·$99/mo | approved | 7.6 | View → | |
| 14 | Henry Meds GLP-1 | Compounded Semaglutide / Tirzepatide | $297/mo | compounded | 7.6 | View → | |
| 15 | Saxenda | Liraglutide | $1349/mo | approved | 7.3 | View → |
Summary
Our recommendations for weight loss
A short read of who wins for which kind of patient.
- Foundayo (orforglipron) · Editor's Choice — Eli Lilly oral GLP-1 pill for weight loss (Apr 2026 launch)
Recommendation labels are computed from each product’s editorial badges + scoring rubric. See methodology for the full rubric — page /best-glp1-for/weight-loss.
Evidence
What the trials show
STEP 1 (NEJM 2021, n=1961) showed semaglutide 2.4 mg produced 14.9% mean body-weight loss at week 68 vs 2.4% on placebo, with 86.4% of patients losing ≥ 5%. SURMOUNT-1 (NEJM 2022, n=2539) showed tirzepatide 15 mg produced 20.9% mean loss at week 72 on the treatment-regimen (intention-to-treat) estimand — up to 22.5% on the efficacy estimand — vs 3.1% on placebo. SURMOUNT-5, a head-to-head trial, found tirzepatide superior to semaglutide for weight loss. Liraglutide 3.0 mg (SCALE) is the older, lower-efficacy option. An oral semaglutide tablet (Wegovy) became the first FDA-approved oral GLP-1 for weight management in January 2026.
Prescribing
How prescribers handle it
On-label prescribing requires BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea). Zepbound and Wegovy are the first-line injectables; Saxenda (daily) is largely superseded. Mounjaro and Ozempic are the diabetes-indicated molecules and are increasingly denied for off-label weight-loss use in 2026 — use the weight-loss-indicated brand to match the FDA label.
Insurance
How coverage works
Commercial PA approval hinges on documenting BMI plus comorbidity against the FDA label. Plans that exclude weight-loss drugs entirely will not approve any pathway on BMI alone; an adjacent on-label indication (OSA-with-obesity for Zepbound, established ASCVD for Wegovy) is often the only route. NovoCare and LillyDirect cash-pay channels work regardless of coverage.
Cautions
Boxed warning for risk of thyroid C-cell tumors; contraindicated in personal/family history of medullary thyroid carcinoma or MEN 2. Most common adverse events are GI (nausea, vomiting, diarrhea). Roughly 25-40% of weight lost can be lean body mass without resistance training and adequate protein (1.2-1.6 g/kg). Weight regain is common after discontinuation.
Editorial verdict
What we recommend
This is the indication with the strongest, most replicated evidence in the category. For BMI ≥ 30, or ≥ 27 with a comorbidity, tirzepatide (Zepbound) has the highest published efficacy; semaglutide (Wegovy) has the deepest cardiovascular and long-term safety dataset. Plan for chronic, not time-limited, therapy and prioritize protein and resistance training to protect lean mass.
Frequently asked questions
Which GLP-1 is best for weight loss?+
Our #1 pick is Form Health. It scored highest on effectiveness and safety for weight loss based on our clinical rubric.
What does the evidence show for GLP-1 medications and weight loss?+
STEP 1 (NEJM 2021, n=1961) showed semaglutide 2.4 mg produced 14.9% mean body-weight loss at week 68 vs 2.4% on placebo, with 86.4% of patients losing ≥ 5%. SURMOUNT-1 (NEJM 2022, n=2539) showed tirzepatide 15 mg produced 20.9% mean loss at week 72 on the treatment-regimen (intention-to-treat) estimand — up to 22.5% on the efficacy estimand — vs 3.1% on placebo. SURMOUNT-5, a head-to-head trial, found tirzepatide superior to semaglutide for weight loss. Liraglutide 3.0 mg (SCALE) is the older, lower-efficacy option. An oral semaglutide tablet (Wegovy) became the first FDA-approved oral GLP-1 for weight management in January 2026.
Does insurance cover GLP-1 medications for weight loss?+
Commercial PA approval hinges on documenting BMI plus comorbidity against the FDA label. Plans that exclude weight-loss drugs entirely will not approve any pathway on BMI alone; an adjacent on-label indication (OSA-with-obesity for Zepbound, established ASCVD for Wegovy) is often the only route. NovoCare and LillyDirect cash-pay channels work regardless of coverage.
Are GLP-1 medications safe for weight loss?+
Boxed warning for risk of thyroid C-cell tumors; contraindicated in personal/family history of medullary thyroid carcinoma or MEN 2. Most common adverse events are GI (nausea, vomiting, diarrhea). Roughly 25-40% of weight lost can be lean body mass without resistance training and adequate protein (1.2-1.6 g/kg). Weight regain is common after discontinuation.
The bottom line
Best GLP-1 for weight loss
This is the indication with the strongest, most replicated evidence in the category. For BMI ≥ 30, or ≥ 27 with a comorbidity, tirzepatide (Zepbound) has the highest published efficacy; semaglutide (Wegovy) has the deepest cardiovascular and long-term safety dataset. Plan for chronic, not time-limited, therapy and prioritize protein and resistance training to protect lean mass.